After listening to the webinar, not much changes in the short...

After listening to the webinar, not much changes in the short term. They pretty much avoid talk on price of the implant and the stagnant geographical expansion of scenesse. Seems if the price adjusted down it may open up further jurisdictions? Not my business decision to make though.
Probably more important than these financials is WB departing and what other board positions happen. With no WB they are lacking the business experience and are seemingly weighted towards the medical side. If Brenda was to depart also, I expect and would hope they appoint an experienced business leader. Some say cash is King and there has been some method to the madness of cash accumulation. Perhaps the quickest path to revenue growth would be an acquisition but I have no idea what or when that might be. SP shouldn't get much lower if the trials are successful. In the mean time don't expect a significant rise either unless some surprise happens. (or a buyback!!) GLTA